A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Stopped early · Phase 3

Conditions studied: Pyoderma Gangrenosum

In brief

The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers

Key facts

Study ID

NCT02318914

Run by

XOMA (US) LLC

People needed

15

Starts

2014-11-01

Expected to finish

2016-02-01

Last updated by the study team

2016-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals who participated in a previous study of gevokizumab in PG
• A clinical diagnosis of classic pyoderma gangrenosum
• Contraceptive measures adequate to prevent pregnancy during the study

You may not qualify if…

• Clinical evidence of acutely infected pyoderma gangrenosum
• History of allergic or anaphylactic reactions to monoclonal antibodies
• History of recurrent or chronic systemic infections
• Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Oceanside, California, United States
• Study site — San Diego, California, United States
• Study site — Farmington, Connecticut, United States
• Study site — Coral Gables, Florida, United States
• Study site — Miami, Florida, United States
• Study site — North Miami Beach, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Macon, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Springfield, Illinois, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Henderson, Nevada, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — New York, New York, United States
• Study site — Rochester, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.